Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. The growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. This marks a critical milestone for Tonix as it transitions from a development-stage company to a commercial-stage biotech with a flagship product gaining traction in the market.
During the quarter, TONMYA recorded 12,592 total prescriptions, reflecting a 100% sequential increase. New patient prescriptions rose 36%, while refills surged 207%, indicating strong patient adherence and growing physician adoption. The drug's coverage now represents approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to roughly 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027, further enhancing patient access and potential revenue growth.
The impressive sales figures underscore the unmet medical need in fibromyalgia, a condition that has seen no new treatments in over 15 years. TONMYA's launch appears to be filling a significant gap, and the robust prescription trends suggest that it is gaining acceptance among healthcare providers and patients. The revenue growth also provides Tonix with a stronger financial foundation to support its ongoing clinical pipeline and commercialization efforts.
Beyond TONMYA, Tonix continues to advance its clinical programs. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder (MDD). This study could open new indications for the drug, expanding its market potential. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These pipeline developments highlight Tonix's commitment to addressing high unmet medical needs in CNS and immunology.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that these resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as Tonix continues to invest in TONMYA's commercial rollout and its late-stage clinical trials.
The strong quarterly performance is a positive signal for investors, demonstrating that Tonix can successfully commercialize its products and generate meaningful revenue. The growth in TONMYA sales is particularly noteworthy, as fibromyalgia affects millions of patients, and TONMYA is the first new treatment approved for this condition in more than 15 years. The company's focus on expanding coverage and driving prescription growth positions it well for sustained market penetration.
Moreover, the advancement of the pipeline, especially the MDD program, could provide additional growth catalysts in the coming years. If TNX-102 SL proves effective in MDD, it could address a much larger patient population and significantly boost the company's revenue potential. Similarly, the Lyme disease prophylaxis program addresses a growing public health concern, and success in that indication could open new revenue streams.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the company's flagship medicine. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. In addition to the MDD and Lyme disease programs, Tonix's pipeline includes TNX-2900 for Prader-Willi syndrome and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection. These programs reflect the company's broad research and development efforts.
As Tonix continues to execute on its commercial and clinical strategies, the company is positioned to make significant strides in addressing diseases with high unmet medical needs. The second-quarter results demonstrate momentum that could be pivotal for the company's future growth.
